DiaSorin falls as Qiagen cuts outlook on QuantiFERON weakness

Biomerieux SA

28/04/2026 09:44

** Shares in Italian medical diagnostics group DiaSorin fall over 4% after Dutch peer Qiagen QIA.DE cuts its sales and profit outlook, underscoring a difficult market for the sector

** Qiagen says outlook downgrade is driven by weaker QuantiFERON immigration testing demand, ongoing caution among U.S. life sciences customers and rising geopolitical uncertainty

** "Qiagen's profit warning follows that of bioMérieux, highlighting a challenging market environment for diagnostics players... the sharp slowdown in QuantiFERON sales is more surprising," Equita says

** The broker notes QuantiFERON is "particularly relevant" for DiaSorin, as it accounts for around 9% of its revenues

     ** Banca Akros says sales decline in QuantiFERON tests could hit DiaSorin revenues more than previously estimated. In March, DiaSorin flagged a fall in Q1 organic sales

** YTD, DiaSorin shares are down over 15%

 (Reporting by Philippe Leroy Beaulieu in Gdansk)

 ((philippe.leroybeaulieu@tr.com))